Jones Financial Companies Lllp boosted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by ...

Collegium Pharmaceutical is executing on commercializing its drugs and growing sales. Click here to find out why COLL stock ...

It's often challenging to decide which stocks to invest in. However, some companies look too attractive to pass up. We asked ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

The agency approved it based on two Phase III studies showing the drug to be as effective as another combination therapy at improving lung function.

Vertex announced that the United Kingdom Medicines and Healthcare products Regulatory Agency has granted approval for ALYFTREK, a once-daily ...

Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success ...

Zacks Research lowered its Q3 2026 earnings estimate for Vertex Pharmaceuticals from $4.15 to $4.13 per share. Other analysts ...

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

AbbVie made a $350 million upfront payment to Gubra for rights to the drug, called GUB014295. Gubra is also eligible to receive another $1.9 billion if certain development and sales milestones are met ...

The stock's fall snapped a four-day winning streak.

The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...